Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $27

Arcturus Therapeutics

Arcturus Therapeutics

ARCT

0.00

Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ: ARCT) with a Buy rating and announces Price Target of $27.